Shionogi & Co. Ltd. has announced the renewal of its mid-term 10-year strategy plan, this time covering the period to 2030.
Following the successful performance of infectious disease products, including its oral COVID-19 therapeutic Xocova (ensitrelvir) in Japan and the antibiotic...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
